S'abonner

Nasopharyngeal bacterial burden and antibiotics: Influence on inflammatory markers and disease severity in infants with respiratory syncytial virus bronchiolitis - 14/12/17

Doi : 10.1016/j.jinf.2015.06.010 
M. Carmen Suárez-Arrabal a, i , Cesar Mella a, b, j , Santiago M. Lopez a, Nicole V. Brown c, Mark W. Hall b, Sue Hammond d, William Shiels e, Judith Groner f, Mario Marcon g, Octavio Ramilo a, h, Asuncion Mejias a, h,
a Center for Vaccines and Immunity, The Research Institute at Nationwide Children's Hospital, Columbus, OH, USA 
b Division of Critical Care Medicine, Nationwide Children's Hospital and The Ohio State University School of Medicine, Columbus, OH, USA 
c Center for Biostatistics, The Ohio State University, Columbus, OH, USA 
d Department of Pathology, Nationwide Children's Hospital and The Ohio State University School of Medicine, Columbus, OH, USA 
e Department of Radiology, Nationwide Children's Hospital and The Ohio State University School of Medicine, Columbus, OH, USA 
f Section of Ambulatory Pediatrics, Nationwide Children's Hospital and The Ohio State University School of Medicine, Columbus, OH, USA 
g Department of Microbiology and Laboratory Medicine, Nationwide Children's Hospital and The Ohio State University School of Medicine, Columbus, OH, USA 
h Division of Infectious Diseases, Nationwide Children's Hospital and The Ohio State University School of Medicine, Columbus, OH, USA 

Corresponding author. Division of Pediatric Infectious Disease, Center for Vaccines and Immunity, The Research Institute at Nationwide Children's Hospital, The Ohio State University College of Medicine, 700 Children's Drive, WA 4022, Columbus, OH 43205, USA. Tel.: +1 614 355 2949; fax: +1 614 722 3680.

Summary

Objectives

Animal studies suggest that RSV increases nasopharyngeal (NP) bacterial colonization facilitating bacterial infections. We investigated the influence of antibiotic treatment and colonization with potentially pathogenic bacteria on inflammatory markers and disease severity in RSV-infected in infants.

Methods

Healthy young infants hospitalized with RSV bronchiolitis (n = 136) and age-matched healthy controls (n = 23) were enrolled and NP samples cultured for potentially pathogenic bacteria including: Gram-positive bacteria (GPB): Staphylococcus aureus, Streptococcus pneumoniae, β-hemolytic Streptococcus; and Gram-negative bacteria (GNB): Moraxella catarrhalis and Haemophilus influenzae. Clinical parameters and plasma IL-8, IL-6 and TNF-α concentrations were compared according to the bacterial class and antibiotic treatment.

Results

Antibiotic treatment decreased by 10-fold NP bacterial recovery. Eighty-one percent of RSV infants who did not receive antibiotics before sample collection were colonized with pathogenic bacteria. Overall, GNB were identified in 21% of patients versus 4% of controls who were mostly colonized with GPB. Additionally, in RSV patients NP white blood cell counts (p = 0.026), and blood neutrophils (p = 0.02) were higher in those colonized with potentially pathogenic bacteria versus respiratory flora. RSV patients colonized with GNB had higher plasma IL-8 (p = 0.01) and IL-6 (p < 0.01) concentrations than controls, and required longer duration of oxygen (p = 0.049).

Conclusions

Infants with RSV bronchiolitis colonized with potentially pathogenic bacteria had increased numbers of mucosal and systemic inflammatory cells. Specifically, colonization with GNB was associated with higher concentrations of proinflammatory cytokines and a trend towards increased disease severity.

Le texte complet de cet article est disponible en PDF.

Highlights

Eighty one percent of infants hospitalized with RSV bronchiolitis were colonized with potentially pathogenic bacteria.
Antibiotics were commonly used and associated with longer oxygen need and lobar consolidation in RSV-infected infants.
Overall and Gram-negative (GNB) NP bacterial colonization was more common in RSV-infected infants vs. healthy controls.
RSV-infected infants colonized with GNB had increased mucosal and blood neutrophil numbers, plasma IL-6 and IL-8 and duration of oxygen.

Le texte complet de cet article est disponible en PDF.

Keywords : Nasopharyngeal bacterial colonization, Bronchiolitis, RSV, Disease severity, Gram-negative bacteria, Antibiotics


Plan


 This work was presented in part at the European Society for Pediatric Infectious Diseases 30th Annual Meeting. Thessaloniki, Greece, May 8–12, 2012.


© 2015  The British Infection Association. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 71 - N° 4

P. 458-469 - octobre 2015 Retour au numéro
Article précédent Article précédent
  • Clinical MRSA isolates from skin and soft tissue infections show increased in vitro production of phenol soluble modulins
  • Nicholas R. Berlon, Robert Qi, Batu K. Sharma-Kuinkel, Hwang-Soo Joo, Lawrence P. Park, Dennis George, Joshua T. Thaden, Julia A. Messina, Stacey A. Maskarinec, Manica Mueller-Premru, Eugene Athan, Pierre Tattevin, Juan M. Pericas, Christopher W. Woods, Michael Otto, Vance G. Fowler
| Article suivant Article suivant
  • The role of live poultry movement and live bird market biosecurity in the epidemiology of influenza A (H7N9): A cross-sectional observational study in four eastern China provinces
  • Xiaoyan Zhou, Yin Li, Youming Wang, John Edwards, Fusheng Guo, Archie C.A. Clements, Baoxu Huang, Ricardo J. Soares Magalhaes

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.